Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke

Int J Mol Sci. 2016 Mar 16;17(3):390. doi: 10.3390/ijms17030390.

Abstract

Stroke, as the leading cause of physical disability and cognitive impairment, has a very significant impact on patients' quality of life (QoL). The objective of this study is to know the effect of citicoline treatment in Qol and cognitive performance in the long-term in patients with a first ischemic stroke. This is an open-label, randomized, parallel study of citicoline vs. usual treatment. All subjects were selected 6 weeks after suffering a first ischemic stroke and randomized into parallel arms. Neuropsychological evaluation was performed at 1 month, 6 months, 1 year and 2 years after stroke, and QoL was measured using the EuroQoL-5D questionnaire at 2 years. 163 patients were followed during 2 years. The mean age was 67.5 years-old, and 50.9% were women. Age and absence of citicoline treatment were independent predictors of both utility and poor quality of life. Patients with cognitive impairment had a poorer QoL at 2 years (0.55 vs. 0.66 in utility, p = 0.015). Citicoline treatment improved significantly cognitive status during follow-up (p = 0.005). In conclusion, treatment with long-term citicoline is associated with a better QoL and improves cognitive status 2 years after a first ischemic stroke.

Keywords: citicoline; cognitive impairment; ischemic stroke; quality of life.

MeSH terms

  • Aged
  • Brain Ischemia / complications*
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / prevention & control*
  • Cytidine Diphosphate Choline / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Quality of Life*
  • Random Allocation
  • Stroke / complications*
  • Stroke / etiology

Substances

  • Cytidine Diphosphate Choline